| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331, 2020 | 1088 | 2020 |
| Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 A Bonaventura, A Vecchié, L Dagna, K Martinod, DL Dixon, ... Nature Reviews Immunology 21 (5), 319-329, 2021 | 934 | 2021 |
| Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis F Ciceri, L Beretta, AM Scandroglio, S Colombo, G Landoni, A Ruggeri, ... Critical care and resuscitation 22 (2), 95-97, 2020 | 666 | 2020 |
| Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease EL Diamond, L Dagna, DM Hyman, G Cavalli, F Janku, J Estrada-Veras, ... Blood, The Journal of the American Society of Hematology 124 (4), 483-492, 2014 | 629 | 2014 |
| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 521 | 2021 |
| Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study C Campochiaro, E Della-Torre, G Cavalli, G De Luca, M Ripa, N Boffini, ... European journal of internal medicine 76, 43-49, 2020 | 456 | 2020 |
| Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors M Ripa, L Galli, A Poli, C Oltolini, V Spagnuolo, A Mastrangelo, C Muccini, ... Clinical Microbiology and Infection 27 (3), 451-457, 2021 | 395 | 2021 |
| Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency A Zangrillo, L Beretta, P Silvani, S Colombo, AM Scandroglio, ... Critical care and resuscitation 22 (2), 91-94, 2020 | 383 | 2020 |
| Eosinophils from physiology to disease: a comprehensive review GA Ramirez, MR Yacoub, M Ripa, D Mannina, A Cariddi, N Saporiti, ... BioMed research international 2018 (1), 9095275, 2018 | 354 | 2018 |
| Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy F Ciceri, A Castagna, P Rovere-Querini, F De Cobelli, A Ruggeri, L Galli, ... Clinical immunology 217, 108509, 2020 | 344 | 2020 |
| Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era G Goyal, ML Heaney, M Collin, F Cohen-Aubart, A Vaglio, BH Durham, ... Blood, The Journal of the American Society of Hematology 135 (22), 1929-1945, 2020 | 317 | 2020 |
| Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy A Zangrillo, L Beretta, AM Scandroglio, G Monti, E Fominskiy, S Colombo, ... Critical Care and Resuscitation 22 (3), 200-211, 2020 | 298 | 2020 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 280 | 2021 |
| Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study E Della-Torre, C Campochiaro, G Cavalli, G De Luca, A Napolitano, ... Annals of the rheumatic diseases 79 (10), 1277-1285, 2020 | 255 | 2020 |
| GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473, 2020 | 231 | 2020 |
| The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases G Cavalli, B Guglielmi, A Berti, C Campochiaro, MG Sabbadini, L Dagna Annals of the rheumatic diseases 72 (10), 1691-1695, 2013 | 225 | 2013 |
| Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation G Peretto, S Sala, S Rizzo, A Palmisano, A Esposito, F De Cobelli, ... Journal of the American College of Cardiology 75 (9), 1046-1057, 2020 | 220 | 2020 |
| Human γδ T cells: a nonredundant system in the immune-surveillance against cancer M Ferrarini, E Ferrero, L Dagna, A Poggi, MR Zocchi Trends in immunology 23 (1), 14-18, 2002 | 216 | 2002 |
| Pentraxin-3 as a marker of disease activity in Takayasu arteritis L Dagna, F Salvo, M Tiraboschi, EP Bozzolo, S Franchini, C Doglioni, ... Annals of internal medicine 155 (7), 425-433, 2011 | 204 | 2011 |
| Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study G Cavalli, A Larcher, A Tomelleri, C Campochiaro, E Della-Torre, ... The Lancet Rheumatology 3 (4), e253-e261, 2021 | 178 | 2021 |
